Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: **NEW ASSIGNMENT** NATURE OF CONVEYANCE: **ASSIGNMENT**

CONVEYING PARTY DATA

Name	Execution Date
Afferent Therapeutics, LLC	09/25/2007

RECEIVING PARTY DATA

Name:	Aciex, Inc.	
Street Address:	863 Turnpike Street	
City:	North Andover	
State/Country:	MASSACHUSETTS	
Postal Code:	01845	

PROPERTY NUMBERS Total: 10

Property Type	Number
Application Number:	11698778
Application Number:	11807147
Application Number:	11820461
Application Number:	11890030
Application Number:	60845479
Application Number:	11796278
Application Number:	11074000
Application Number:	60904209
PCT Number:	US0761065
PCT Number:	US0710177

CORRESPONDENCE DATA

Fax Number: (650)324-0638

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

650 324-7000 Phone:

Email: smanibusan@hewm.com

PATENT

500362421 **REEL: 019879 FRAME: 0357**

Correspondent Name: Paul Davis

Address Line 1: 275 Middlefield Road

Address Line 4: Menlo Park, CALIFORNIA 94025

ATTORNEY DOCKET NUMBER: 23948/0054

NAME OF SUBMITTER: Paul Davis

Total Attachments: 2

source=Aciexassignment#page1.tif source=Aciexassignment#page2.tif

PATENT REEL: 019879 FRAME: 0358

PATENT ASSIGNMENT

This Patent Assignment, dated as of September 25, 2007 (the "Effective Date"), is made by and between ACIEX, INC., a Delaware limited liability company located at 863 Turnpike Street, North Andover, MA 01845 ("Assignee"), and AFFERENT THERAPEUTICS, LLC, a Delaware corporation located at 863 Turnpike Street, North Andover, MA 01845 ("Afferent"). Defined terms used but not defined herein shall have the meanings ascribed to them in that certain IP Contribution Agreement, dated as of September 25, 2007, by and between Assignee and Afferent (the "IP Contribution Agreement").

WHEREAS, Afferent delivers this Patent Assignment to Assignee pursuant to the IP Contribution Agreement.

NOW, THEREFORE, effective as of the Effective Date, Afferent hereby assigns, transfers, conveys and delivers to Assignee and its successors, assigns and legal representatives:

- (i) all of Afferent's rights, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patent applications set forth on Schedule A and filed with the U.S. Patent and Trademark Office, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor;
- (ii) the entire right, title and interest in and to any patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and
- (iii) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the inventions, discoveries and applications disclosed in the patent applications set forth on Schedule A.

FURTHER, Afferent hereby authorizes and requests the competent authorities to grant and to issue any and all such patents in the United States and throughout the world to Assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by Afferent had this assignment not been made.

IN WITNESS WHEREOF, Afferent has caused this Patent Assignment to be signed by its representative thereunto duly authorized, as of the Effective Date.

AFFERENT THERAPEUTICS, LLC

By: Afferent Venture Partners, LLC, its Manager

_

Title:

MANDER

SCHEDULE A

Product Patents

- 1. United States Patent Application No. 11/698,778 (Formulations and Methods for Treating Dry Eye)
- 2. United States Patent Application No. 11/807,147 (Formulations and Methods for Treating Dry Eye)
- 3. United States Patent Application No. 11/820,461 (Formulations and Methods for Treating Dry Eye)
- 4. United States Patent Application No. 11/890,030 (Formulations and Methods for Treating Dry Eye)
- 5. United States Patent Application No. 60/845,479 (Compositions for the Treatment and Prevention of Eyelid Swelling)
- 6. United States Patent Application No. 11/796,278 (Compositions for the Treatment and Prevention of Eyelid Swelling)
- 7. United States Patent Application No. 11/074,000 (Novel topical ophthalmic formulations)
- 8. United States Patent Application No. 60/904,209 (Methods and Compositions for Treating and Preventing Lid Margin Inflammation)
- 9. PCT Patent Application No. PCT/US07/61065 (Formulations and Methods for Treating Dry Eye)
- 10. PCT Patent Application No. PCT/US07/010177 (Compositions for the Treatment and Prevention of Eyelid Swelling)

PATENT REEL: 019879 FRAME: 0360

RECORDED: 09/26/2007